Parkinson Progression Marker Initiative Online (PPMI Online)

November 21, 2024 updated by: Caroline M Tanner, Michael J. Fox Foundation for Parkinson's Research

Parkinson's Progression Markers Initiative Online Study (PPMI Online)

Parkinson Progression Marker Initiative Online (PPMI Online) is an observational study collecting participant reported information from people with and without Parkinson's disease (PD), for the goal of better understanding risk and predictive factors for PD.

PPMI Online is part of the broader Parkinson Progression Marker Initiative aimed at identifying markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

PPMI is a broad program that is expanding the goals of the original PPMI study, and will include this PPMI Online protocol, as well the PPMI Clinical [NCT04477785], PPMI Remote, PPMI Digital protocols (with external regulatory oversight). All participants in PPMI may be asked to participate in one or all of these protocols and their enrollment in these studies may occur in varying order. PPMI participants may also be asked to participate in additional PPMI companion studies (as they are developed), which may only involve a subset of PPMI participants based on their cohort designation

Study Type

Observational

Enrollment (Estimated)

500000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: University of California, San Francisco
  • Phone Number: 877-525-7764
  • Email: info@ppmionline.org

Study Locations

  • United States
    • California
      • San Francisco, California, United States, 94143
        • Recruiting
        • UCSF Movement Disorders and Neuromodulation Center (MDNC)
        • Contact:
          • UCSF
          • Phone Number: 877-525-7764

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

In PPMI Online, up to 500,000 participants with and without PD will be enrolled and contribute data longitudinally and cross-sectionally using a web-based platform.

Description

Inclusion Criteria:

  • Parkinson Disease (PD) Participants:

    • Male or female age 18 years or older.
    • Has received a diagnosis of Parkinson's disease

Participants without PD:

  • Male or female age 18 years or older.
  • Has not received a diagnosis of Parkinson's disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Unified Parkinson's Disease Rating Scale Ib & II
Time Frame: Baseline to 240 months
Evaluates self-reported motor and nonmotor Parkinson's disease symptoms
Baseline to 240 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Michael J. Fox Foundation for Parkinson's Research

Investigators

  • Principal Investigator: Kenneth L Marek, MD, Institute For Neurodegenerative Disorders
  • Principal Investigator: Caroline Tanner, MD, PhD, University of California, San Francisco

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 28, 2021

Primary Completion (Estimated)

December 1, 2041

Study Completion (Estimated)

December 1, 2041

Study Registration Dates

First Submitted

September 2, 2021

First Submitted That Met QC Criteria

September 23, 2021

First Posted (Actual)

October 1, 2021

Study Record Updates

Last Update Posted (Estimated)

November 25, 2024

Last Update Submitted That Met QC Criteria

November 21, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PPMI-007

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Observation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe